• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

“No Evidence of Disease Activity” may be useful goal in multiple sclerosis

byAshley AaroeandJames Jiang
December 25, 2014
in Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Status of “No Evidence of Disease Activity” or NEDA is defined as no new clinical or radiographic evidence of multiple sclerosis (MS) disease progression.

2. NEDA at 2 years of follow-up had a positive predictive value of 78.3% for no progression at 7 years. Thus, NEDA status may represent a useful outcome measure in describing the prognosis and treatment of MS.

Evidence Rating Level: 2 (Good)       

Study Rundown: As a means of assessing prognosis and treatment efficacy for multiple sclerosis (MS), this study hypothesized that a clinical status of “no evidence of disease activity” (NEDA) would provide a useful outcome measure. NEDA is defined as the absence of new or enlarging T2 or T1 gadolinium-enhancing lesions on MRI, and no clinical relapse or sustained increased score on the Expanded Disability Status Scale (EDSS). This study sought to follow a cohort of patients with relapsing-remitting MS over the course of seven years. They were seen in clinic every six months, and underwent an MRI study annually.

The study found that NEDA at 2 years predicted NEDA at 5 years, as well as the level of disability patients experienced after 7 years of follow-up. NEDA is a combined measure, incorporating both clinical and radiographic information, and this study suggests that as an outcome measure it is more effective than any one variable alone. The large, diverse cohort in this study will be studied on an ongoing basis by the authors and their collaborators. In the future, it may be useful to incorporate biomarkers in blood and cerebrospinal fluid into the NEDA measure as well in order to better refine the definition of this variable.

Click to read the study, published today in JAMA Neurology

Relevant Reading: Disease Activity Free Status: A New End Point for a New Era in Multiple Sclerosis Clinical Research?

RELATED REPORTS

United States medical cannabis registration increased significantly between 2016 and 2020

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

In-Depth [prospective cohort]: Patients were selected from the Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women’s Hospital (CLIMB) cohort. These patients had a minimum of 7 years of prospective follow-up with yearly brain MRI and biannual clinic visits. Ultimately, 219 patients between 18 to 65 years of age were recruited. Clinical examinations and EDSS scores were performed at 6-month intervals. In this study, relapse was defined as new symptoms or signs that lasted for more than 24 hours without other likely cause. EDSS score increases of more than one that persisted over two clinical visits were classified as representing progression of the disease.

At one year, 99 of 215 patients included in final analysis met NEDA criteria (i.e., no clinical or radiographic disease activity, described further above). At 2 years, 60 of 218 patients still met NEDA status. Only 17 of 216 patients met NEDA status at 7 years. The positive predictive value of NEDA status in predicting absence of disease progression or no change in EDSS at 7 years was 71.7% at 1 year and 78.3% at 2 years. There were no differences found for patients determined to have established disease as compared to early disease.

More from this author: Hyperbaric oxygen does not significantly improve post-concussion symptoms, Increased orexin levels linked with poor sleep quality in Alzheimer Disease, Antibiotic prescription patterns in China may contribute to resistance, Glatiramer acetate (Copaxone) therapy may alter B cell function in multiple sclerosis

Image: CC/Oliver Stollmann

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: multiple sclerosis
Previous Post

No decrease in infant mortality with maternal micronutrient supplementation in Bangladesh

Next Post

Radiologist recommendations often yield significant findings

RelatedReports

Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

United States medical cannabis registration increased significantly between 2016 and 2020

June 29, 2022
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

October 12, 2021
Quick Take: Safety and Efficacy of Ozanimod Versus Interferon Beta-1a in Relapsing Multiple Sclerosis (SUNBEAM)
Chronic Disease

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

August 17, 2021
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Improvements in therapeutic and managing standards associated with significant reduction in risk of persistent disability in patients with pediatric-onset multiple sclerosis

June 2, 2021
Next Post
Radiologist recommendations often yield significant findings

Radiologist recommendations often yield significant findings

The ZEUS study: everolimus maintains durable renal transplant function

The ZEUS study: everolimus maintains durable renal transplant function

Social integration may reduce suicide risk in male health professionals

Childhood adversity linked with increased adult psychiatric medication use

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.